CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients
01 sept. 2023 08h00 HE
|
Centogene NV
Results from pivotal study published in Diagnostics journalConfirmation of utility of lyso-Gb1 (glucosylsphingosine) as a sensitive biomarker for Gaucher diseaseCould predict clinical course of...
Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein
01 sept. 2023 02h00 HE
|
Ultragenyx Pharmaceutical Inc.
BERLIN, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuer Therapien für seltene genetische...
CENTOGENE Accelerates Global Genetic Data Interpretation, Launching FilterTool Application as Accessory to CentoCloud® Bioinformatics Pipeline
26 avr. 2023 08h30 HE
|
Centogene NV
Enabling Rapid and Reliable Diagnosis and Research of Rare Genetic Diseases Around the World CENTOGENE’s FilterTool aims to fuel rapid, reliable analysis for diagnosis and research of rare genetic...
CENTOGENE Launches NEW CentoGenome®, World’s Most Comprehensive Whole Genome Sequencing Solution for Diagnosis of Rare and Neurodegenerative Diseases
12 avr. 2023 06h30 HE
|
Centogene NV
Aims to resolve patient diagnostic odyssey, often spanning years and multiple misdiagnoses before accurate diagnosisCombines cutting-edge technology and streamlined CE-IVD bioinformatics pipeline with...
Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook
17 janv. 2023 08h00 HE
|
Idera Pharmaceuticals, Inc.
Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple...
Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
14 nov. 2022 16h05 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and...
CENTOGENE Announces Expansion of Data Access and Collaboration Agreement With Pfizer
17 mars 2022 06h30 HE
|
Centogene NV
In November 2019, CENTOGENE first announced the signing of a data access and collaboration agreement to discover and validate novel genetic and biochemical targets for the potential development of new...
PacBio Supports SickKids to Investigate Use of HiFi Sequencing in Undiagnosed Genetic Conditions
28 févr. 2022 09h00 HE
|
PacBio
MENLO PARK, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- PacBio, a leading provider of high-quality, highly accurate sequencing platforms, today announced it will be supporting The Hospital for Sick...
KK Women’s and Children’s Hospital and PacBio Collaborate in Asia’s First Study of Unexplained Neurodevelopmental Disorders
16 févr. 2022 09h00 HE
|
PacBio
SINGAPORE and MENLO PARK, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- KK Women’s and Children’s Hospital (KKH) and PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate sequencing...
PacBio Announces Collaboration with Genomics England to Sequence Biobanked Rare Disease Samples Using HiFi Sequencing Technology
11 janv. 2022 07h10 HE
|
Pacific Biosciences of California, Inc.
MENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a collaboration with Genomics...